Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.28Last Year’s EPS
1.21Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 28, 2025
|% Change Since: 7.11%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
ANI Pharmaceuticals demonstrated strong performance in 2024, with record results and increased guidance for 2025. The company showed significant growth in its Rare Disease and Generics businesses and completed a strategic acquisition. However, there are challenges related to market access for ILUVIEN and YUTIQ and potential disruptions due to manufacturing transitions. Despite these challenges, the positive momentum and strategic initiatives in place suggest a cautiously optimistic outlook.Company Guidance
During ANI Pharmaceuticals' fourth quarter 2024 earnings call, the company announced an increase in their 2025 guidance for total revenues and adjusted non-GAAP EBITDA, citing strong performance and growth initiatives. For 2025, ANI expects revenue to range between $756 million and $776 million, marking a 23% to 26% growth over 2024, compared to their prior forecast of $739 million to $759 million. The adjusted non-GAAP EBITDA is projected to be between $190 million and $200 million, reflecting a 22% to 28% increase over the prior year’s expectations of $182 million to $192 million. Key growth drivers include higher demand for Cortrophin Gel, anticipated revenue from new ophthalmology products ILUVIEN and YUTIQ, and generics, including the launch of Prucalopride. Cortrophin Gel alone is forecasted to generate between $265 million and $274 million, representing a 34% to 38% increase, while ILUVIEN and YUTIQ are expected to contribute $97 million to $103 million in sales. The company also emphasized strategic growth through acquisitions and operational efficiencies, including the expansion of their ophthalmology sales team and clinical trial investments.Record Fourth Quarter and Full Year Results
ANI Pharmaceuticals reported record fourth quarter and full year 2024 results, with total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS all coming in above previously announced guidance.
Increased 2025 Revenue and EBITDA Guidance
The company raised its 2025 guidance for total revenues to $756 million to $776 million, representing growth of 23% to 26%, and adjusted non-GAAP EBITDA to $190 million to $200 million, reflecting growth of 22% to 28% over 2024.
Strong Growth in Cortrophin Gel
Cortrophin Gel generated $59.4 million in revenues during Q4 2024, up 42% over Q4 2023. The product continues on a strong multiyear growth trajectory with expected revenues to grow between 34% and 38% in 2025.
Generics Business Growth
The Generics business delivered 12% revenue growth in 2024, driven by operational excellence and new product launches. The business is expected to achieve low double-digit growth in 2025.
Successful Acquisition of Alimera Sciences
ANI expanded its rare disease franchise with the acquisition of Alimera Sciences, adding ophthalmology products ILUVIEN and YUTIQ, which generated $27.6 million in Q4.
---
ANIP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ANIP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 28, 2025 | $54.58 | $61.89 | +13.39% |
| Nov 08, 2024 | $58.38 | $61.44 | +5.24% |
| Aug 06, 2024 | $59.16 | $63.29 | +6.98% |
| May 10, 2024 | $65.88 | $68.05 | +3.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ANI Pharmaceuticals Inc (ANIP) report earnings?
ANI Pharmaceuticals Inc (ANIP) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is ANI Pharmaceuticals Inc (ANIP) earnings time?
ANI Pharmaceuticals Inc (ANIP) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIP EPS forecast?
ANIP EPS forecast for the fiscal quarter 2025 (Q1) is 1.28.
---